Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+16.05%
-12.55%
-15.72%
-2.98%
SKYE
Skye Bioscience Inc.
$1.73
Login to see Skye Bioscience Inc. (SKYE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Upgraded on attractively valued
Chart
$3.86 (-55.18%)
$3.46 (-50.00%)
$3.46 (-50.00%)
$3.46 (-50.00%)
SKYE has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Price under $5
High volatilty
SKYE overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
SKYE Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
SKYE Street view is unimpressive and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displaySKYE Earnings
The TTM reflects 12-month period, providing review of SKYE financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
What is SKYE current stock price?
What are SKYE stock strengths?
What risks are associated with SKYE stock?
When is SKYE next earnings report?
What is SKYE market cap and volume?
What is SKYE's current Stock IQ?
Should I buy SKYE stock right now?
Is SKYE a Strong Buy right now?
What does a 'Strong Buy' rating mean for SKYE?
What does a 'Strong Sell' rating mean for SKYE?
What factors influence SKYE's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+16.05%
-12.55%
-15.72%
-2.98%
SKYE
Skye Bioscience Inc.
Current Price
$1.73
Stock Insights
Strengths
Upgraded on attractively valued
Login to unlock Skye Bioscience Inc. (SKYE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$3.86 (-55.18%)
$3.46 (-50.00%)
$3.46 (-50.00%)
$3.46 (-50.00%)
SKYE Analysts Opinion
SKYE Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
SKYE Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
SKYE Street view is unimpressive and have negative views on the near-term outlook
SKYE has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Price under $5
High volatilty
Average key support and resistance price levels.
Login to displaySKYE Earnings
The TTM data reflects the most recent 12-month period, providing overview of SKYE financial performance.
SKYE Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
SKYE Latest Analysis
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal. Skye Bioscience stock nosedives 60% after its investigational obesity candidate nimacimab fails to meet the key goal in a mid-stage study.
Tue Oct 7, 2025
Nasdaq Jumps Over 150 Points. Skye Bioscience Shares Plunge. United States stocks traded mixed midway through trading with the Nasdaq Composite gaining more than 150 points on Monday.The Dow traded down 0.16% to 46684.03 while the NASDAQ rose 0.71% to 22941.69. The S&.P 500 also rose gaining 0.40% to 6742.80.Check This Out: Information technology shares jumped by 0.9% on Monday.In trading on Monday real estate stocks fell by 0.8%.AMD) shares surged more than 27% on Monday following a landmark
Mon Oct 6, 2025
Skye Says CBeyond Phase 2a Study Of Nimacimab Monotherapy Did Not Meet Primary Endpoint . (RTTNews) - Biotechnology company Skye Bioscience Inc. (SKYE) announced Monday the topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab its peripherally-restricted CB1 inhibitor antibody.
Mon Oct 6, 2025
Skye Bioscience stock plummets after failed weight loss drug trial.
Mon Oct 6, 2025
Skye Bioscience: Promising Nimacimab Data Supports Buy Rating.
Wed Oct 1, 2025
HC Wainwright & Co. Initiates Coverage of Skye Bioscience (SKYE) with Buy Recommendation. Fintel reports that on September 30 2025 HC Wainwright &. Co. initiated coverage of Skye Bioscience (NasdaqGM:SKYE) with a Buy recommendation. Analyst Price Forecast Suggests 294.33% Upside
Tue Sep 30, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
SKYE Stock trends
SKYE Stock performance
SKYE Stock analysis
SKYE investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings
Leaders